{"nctId":"NCT00576303","briefTitle":"A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.","startDateStruct":{"date":"2008-04"},"conditions":["Anemia"],"count":200,"armGroups":[{"label":"RO0503821 (C.E.R.A.), 1x/4weeks","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta [Mircera]"]}],"interventions":[{"name":"methoxy polyethylene glycol-epoetin beta [Mircera]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* chronic renal anemia;\n* hemodialysis or peritoneal dialysis, with same mode of dialysis for \\>=3 months before and throughout screening period;\n* continuous maintenance epoetin alfa or beta therapy with the same dosing interval during the previous 2 months.\n\nExclusion Criteria:\n\n* transfusion of red blood cells during previous 2 months;\n* poorly controlled hypertension requiring interruption of epoetin alfa or beta treatment in past 6 months;\n* significant acute or chronic bleeding such as overt gastrointestinal bleeding;\n* hemolysis;\n* folic acid and vitamin B12 deficiency.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Average Hemoglobin Concentration Within +\\- 1 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter During EEP","description":"All mean Hb values recorded during the evaluation period were calculated and subtracted from the mean baseline Hb value for each participant. The percentage of participants maintaining their mean Hemoglobin (Hb) concentration within +/- 1 gram/deciliter (g/dL) of their reference Hb and between 10.5 -12.5 g/dL is presented during the EEP. The EEP is defined as Week 16 to Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Hb Concentration From Baseline to the EEP","description":"A time adjusted mean change in Hb concentration was calculated using an area under the curve approach, for both periods separately. Change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb value from the average evaluation period Hb value. All blood samples for Hb measurements were taken prior to study drug administration. Analysis used last observation carried forward (LOCF) for missing Hb values to correct for the impact of early dropouts. The baseline period is defined as Week -4 to Week -1. The EEP is defined as Week 16 to Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Average Hb Concentration Within Target Range of 10.5-12.5 g/dL Throughout the EEP","description":"All mean Hb values recorded during the EEP were calculated. The percentage of participants maintaining their average Hb concentration within the targeted range 10.5-12.5 g/dL during the EEP were reported. The EEP is defined as Week 16 to Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of Days Spent Within Hb Range of 10.5-12.5 g/dL During the EEP","description":"The mean number of days the participant spent within the Hb range 10.5-12.5 g/dL during the EEP was reported. The EEP is defined as Week 16 to Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":"18.42"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Any Dose Adjustment During the DTP, EEP, and LTSP","description":"The number of participants who required dose adjustments of C.E.R.A were categorized as; 1. No dose change; 2. Any dose change: a. Dose increase only; b. Dose decrease only; c. Dose increase and increase; 3. Only one dose, all of which were recorded during DTP, EEP and LTSP. DTP is defined as Week 1 to Week 16, EEP is defined as Week 16 to Week 24 and LTSP is defined as Week 24 to Week 44","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Red Blood Cell Transfusion","description":"The number of participants who underwent red blood cell transfusion was reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":200},"commonTop":["Hypertension","Gastritis","Gastritis erosive","Haemorrhoids","Osteoarthritis"]}}}